JAMDA
Volume 11, Issue 3 , Pages 171-178 , March 2010

Managing Diabetes in Long-Term Care Facilities: Benefits of Switching From Human Insulin to Insulin Analogs

  • Naushira Pandya, MD, CMD

      Affiliations

    • Geriatrics Education Center, Nova Southeastern University College of Osteopathic Medicine, Ft. Lauderdale, FL
    • Corresponding Author InformationAddress correspondence to Naushira Pandya, Department of Geriatrics, Geriatrics Education Center, NSU College of Osteopathic Medicine, 3200 S. University Drive, Ft. Lauderdale, FL 33328.
    • ,
  • Esther Nathanson, MD

      Affiliations

    • Watermeadow Medical USA, New York, NY

References 

  1. Travis S, Buchanan R, Wang S, et al. Analyses of nursing home residents with diabetes at admission. J Am Med Dir Assoc. 2004;5:320–327
  2. Resnick H, Heineman J, Stone R, Shorr R. Diabetes in U.S. nursing homes, 2004. Diabetes Care. 2008;31:287–288
  3. American Diabetes Association. Total prevalence of diabetes and pre-diabetes. Available at: http://www.diabetes.org/diabetes-statistics/prevalence.jsp. Accessed September 16, 2008.
  4. American Medical Directors Association. Diabetes Management in the Long-term Care Setting Clinical Practice Guideline. Columbia, MD: AMDA; 2008;
  5. American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32:S13–S61
  6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin- dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  8. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  9. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572
  10. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960–967
  11. Stratton I, Adler A, Neil H, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–412
  12. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431
  13. Dluhy R, McMahon G. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630–2633
  14. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53:298–304
  15. Qaseem A, Vijan S, Snow V, et al. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: The optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007;147:417–422
  16. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geratr Soc. 2003;51:S265–S280
  17. Ryan C, Freed M, Rood J, et al. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006;29:345–351
  18. Xu W, Qiu C, Wahlin Å, et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology. 2004;63:1181–1186
  19. American Dietetic Association. Position paper of the American Dietetic Association: Nutrition across the spectrum of aging. J Am Diet Assoc. 2005;105:616–633
  20. Hendra TJ. Starting insulin therapy in elderly patients. J R Soc Med. 2002;95:453–455
  21. Cryer P, Davis S, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902–1912
  22. Alam T, Weintraub M, Weinreb J. What is the proper use of hemoglobin A1c monitoring in the elderly?. J Am Med Dir Assoc. 2006;7:S60–S64
  23. Lassmann-Vague V. Hypoglycaemia in elderly diabetic patients. Diabetes Metab. 2005;31:5S53–5S57
  24. Mayfield J, Deb P, Potter D. Diabetes and long-term care. In: Harris MI, Cowie CC, Stern MP, et al, eds. Diabeets in America. 2nd ed. Bethesda, MD: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2004. Available from the National Diabetes Information Clearing House and at: http://diabetes.niddk.nih.gov/dm/pubs/america/pdf/chapter28.pdf. Accessed February 20, 2009.
  25. Meyers R, Broton J, Woo-Rippe K, et al. Variability in glycosylated hemoglobin values in diabetic patients living in long-term care facilities. J Am Med Dir Assoc. 2007;8:511–514
  26. Fava S. Role of postprandial hyperglycemia in cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6:859–872
  27. McNabney M, Pandya N, Iwuagwu C, et al. Differences in diabetes management of nursing home patients based on functional and cognitive status. J Am Med Dir Assoc. 2005;6:375–382
  28. Umpierrez G, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30:2181–2186
  29. Pandya N, Thompson S, Sambamoorthi U. The prevalence and persistence of sliding scale insulin use among newly admitted elderly nursing home residents with diabetes mellitus. J Am Med Dir Assoc. 2008;9:663–669
  30. Larkin M, Capasso V, Chen C, et al. Measuring psychological insulin resistance: Barriers to insulin use. Diabetes Educ. 2008;34:511–517
  31. Polonsky W, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care. 2005;28:2543–2545
  32. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26:S18–S24
  33. Levenson S, Morley J. Evidence rocks in long-term care, but does it roll?. J Am Med Dir Assoc. 2007;8:493–501
  34. Zarowitz B, Tangalos E, Hollenack K, O'Shea T. The application of evidence-based principles of care in older persons (Issue 3): Management of diabetes mellitus. J Am Med Dir Assoc. 2006;7:234–240
  35. American Diabetes Association. Economic costs of diabetes in the U.S in 2007. Diabetes Care. 2008;31:1–20
  36. Shetty S, Secnik K, Oglesby A. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Managed Care Pharm. 2005;11:559–564
  37. Gandra S, Lawrence W, Parasuraman B, et al. Total and component healthcare costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Managed Care Pharm. 2006;12:546–554
  38. Williams R, van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia. 2002;45:S13–S17
  39. Stephens J, Botteman M, Hay J. Economic impact of antidiabetic medications and glycemic control on managed care organizations: A review of the literature. J Manag Care Pharm. 2006;12:130–142
  40. Leichter S. Is the use of insulin analogues cost-effective?. Adv Ther. 2008;25:285–299
  41. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD005613
  42. Duckworth W, Davis S. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: A review of clinical studies. J Diabetes Complications. 2007;21:196–204
  43. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004;8(iii):1–57
  44. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–1581
  45. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-treat trial: Randomization addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care. 2003;26:3080–3086
  46. Garber A, Clauson P, Pedersen C, Kølendorf K. Lower risk of hypoglycaemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials. Am J Geriatr Soc. 2007;55:1735–1740
  47. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254–259
  48. Janka HU, Pleewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patient with type 2 diabetes mellitus. J Am Geriatr Soc. 2007;55:182–188
  49. Dornhorst A, Lüddeke HJ, Sreenan S, et al. PREDICTIVE Study Group Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008;62:659–665
  50. Meneghini L, Rosenberg K, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: Clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418–427
  51. Sharplin P, Gordon J, Peters J, et al. Improved glycaemic control by switching from insulin NPH to insulin glargine: A retrospective observational study. Cardiovasc Diabetol. 2009;8:3
  52. Schreiber S, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: An observational study of everyday practice in 12,216 patients. Diabetes Obes Metab. 2006;9:31–38
  53. DeVries J, Nattrass M, Pieber T. Refining basal insulin therapy: What have we learned in the age of analogues?. Diabetes Metab Res Rev. 2007;23:441–454
  54. Qayyum R, Bolen S, Maruther N, et al. Systematic review: Comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008;149:549–559
  55. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human?. Diabetes Obes Metab. 2007;9:630–639
  56. Shestakova M, Sharma S, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: Experiences from the PRESENT study. Curr Med Res Opin. 2007;23:3209–3214
  57. Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract. 2007;61:2009–2018
  58. Davies M, Sinnassamy P, Storms F, Gomis R. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract. 2008;79:368–375
  59. Sharplin P, Gordon J, Peters J, et al. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: A retrospective primary care-based analysis. Cardiovasc Diabetol. 2009;8:9
  60. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56–64
  61. Raslová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193–201
  62. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836–2848
  63. Asakura T, Seino H, Jensen K. Patient acceptance and issues of education of two durable insulin pen devices. Diabetes Technol Ther. 2008;10:299–304
  64. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27:948–962
  65. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27:2495–2497Erratum: Diabetes Care 2004;27:3032
  66. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28:1712–1725
  67. Proos K, Zeinstra J. Impact of insulin delivery devices on insulin errors within a health system. ASHP Midyear Clinical Meeting. Am J Health Syst Pharm. 2006;41;(abstract)
  68. Davis E, Christensen C, Nystrom K, et al. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65:1347–1357
  69. Pawaskar M, Camacho F, Anderson R, et al. Healthcare costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: A retrospective database analysis. Clin Ther. 2007;29:1294–1305
  70. Centers for Disease Control and Prevention (CDC). Transmission of hepatitis B virus among persons undergoing blood glucose monitoring in long-term care facilities—Mississippi, North Carolina, and Los Angeles County, California, 2003-2004. MMWR Morb Mortal Wkly Rep 2005;54:220-223. Available at: http://www.cdc.gov/hepatitis/Populations/PDFs/diabetes_handout.pdf. Accessed February 9, 2008.
  71. Lee J, Botteman M, Nicklasson L, et al. Needlestick injury in acute care nurses caring for patients with diabetes mellitus: a retrospective study. Curr Med Res Opin. 2005;21:741–747
  72. Institute for Safe Medication Practices. Pathways for Medication Safety. Available at: http://www.ismp.org/Tools/PathwaySection1.pdf. Accessed February 5, 2009.

 Financial support for preparation of this manuscript was provided by Novo Nordisk.

PII: S1525-8610(09)00199-6

doi: 10.1016/j.jamda.2009.05.009

JAMDA
Volume 11, Issue 3 , Pages 171-178 , March 2010

Article Tools